



National Library of Medicine

My NCBI  
[Sign In] [Register]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Books

Search **PubMed** for**Go****Clear**
[Limits](#) [Preview/Index](#) [History](#) [Clipboard](#) [Details](#)

 Display  Abstract  Show  20  Sort by  Send to 

All: 1 Review: 1

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: J Psychopharmacol. 2000;14(3):222-7.

Related Articles, Links

### Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia.

**Nath A, Anderson C, Jones M, Maragos W, Booze R, Mactutus C, Bell J, Hauser KF, Mattson M.**

Department of Neurology, University of Kentucky, Lexington, USA.  
anath@pop.uky.edu

Infection with the human immunodeficiency virus (HIV) selectively targets the basal ganglia resulting in loss of dopaminergic neurons. Although frequently asymptomatic, some patients may develop signs of dopamine deficiency de novo. Accordingly, they are highly susceptible to drugs that act on dopaminergic systems. Both neuroleptics and psychostimulants may exacerbate these symptoms. Experimental evidence suggests that viral proteins such as gp120 and Tat can cause toxicity to dopaminergic neurons, and this toxicity is synergistic with compounds such as methamphetamine and cocaine that also act on the dopaminergic system. In addition, other neurotransmitters that modulate dopaminergic function, such as glutamate and opioids, may also modify the susceptibility of the dopamine system to HIV. Therefore, a thorough understanding of the mechanisms that lead to this selective neurotoxicity of dopaminergic neurons would also likely lead to the development of therapeutic modalities for patients with HIV dementia.

#### Publication Types:

- Review
- Review, Tutorial

PMID: 11106300 [PubMed - indexed for MEDLINE]

 Display  Abstract  Show  20  Sort by  Send to 

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 16 2005 14:03:09